A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Phase 2 Terminated 174 enrolled Eli Lilly and Company

RandomizedParallel-groupTriple-blindBasic science

Summary

The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).

Timeline

Start: 2014-04
Primary completion: 2015-09
Completion: 2015-09

Outcome

Outcome not reported

Stopped: “The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.”

Publications

Kazda CM, Frias J, Foga I, Cui X, Guzman CB, Garhyan P, Heilmann C, Yang JA, Hardy TA. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. Diabetes Obes Metab. 2017 Aug;19(8):1071-1077. doi: 10.1111/dom.12904. Epub 2017 Mar 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADOMEGLIVANT	Small molecule	20 mg	Oral
Comparator	Sitagliptin	Small molecule	100 mg	Oral
Background	Metformin	Small molecule	—	Oral
Background	Sulfonylurea	Unknown	—	Oral